These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 22318192

  • 1. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M.
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [Abstract] [Full Text] [Related]

  • 3. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 4. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE.
    Mult Scler; 2011 Aug 15; 17(8):970-9. PubMed ID: 21421809
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC, Leyva L, Oliver B, de Ramón E, Luque G, Fernández V.
    Mult Scler; 2011 Feb 15; 17(2):192-7. PubMed ID: 21088044
    [Abstract] [Full Text] [Related]

  • 6. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 15; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S.
    Mult Scler Relat Disord; 2014 Nov 15; 3(6):705-11. PubMed ID: 25891549
    [Abstract] [Full Text] [Related]

  • 8. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

  • 9. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Miller A, Spada V, Beerkircher D, Kreitman RR.
    Mult Scler; 2008 May 09; 14(4):494-9. PubMed ID: 18208875
    [Abstract] [Full Text] [Related]

  • 10. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 09; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Tysabri® Observational Program (TOP) Investigators.
    Mult Scler Relat Disord; 2018 Aug 09; 24():11-19. PubMed ID: 29860197
    [Abstract] [Full Text] [Related]

  • 12. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L, Sylvia Lawry Centre for Multiple Sclerosis Research.
    Neurology; 2006 Sep 12; 67(5):804-8. PubMed ID: 16966541
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.
    Eur J Neurol; 2010 Jan 12; 17(1):31-7. PubMed ID: 19614963
    [Abstract] [Full Text] [Related]

  • 14. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar 12; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 15. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec 12; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 16. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.
    Laroni A, Gandoglia I, Solaro C, Ribizzi G, Tassinari T, Pizzorno M, Parodi S, Baldassarre G, Rilla MT, Venturi S, Capello E, Sormani MP, Uccelli A, Mancardi GL.
    BMC Neurol; 2014 May 12; 14():103. PubMed ID: 24885703
    [Abstract] [Full Text] [Related]

  • 17. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
    Tasset I, Aguera E, Gascon F, Giraldo AI, Salcedo M, Cruz AH, Sanchez F, Tunez I.
    Rev Neurol; 2012 Apr 16; 54(8):449-52. PubMed ID: 22492096
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC, Engler D, Gholipour T, Weiner H, Bakshi R, Chitnis T.
    J Neurol Sci; 2011 Apr 15; 303(1-2):109-13. PubMed ID: 21251671
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.